Scholarlink

<p>Transcatheter aortic valve implantation (TAVI) using SAPIEN 3 Ultra RESILIA (S3UR) offers improved hemodynamic performance than its former generation, SAPIEN 3 (S3). This study compared 1-year clinical outcomes after TAVI using S3UR and S3. Among 2,369 patients from the OCEAN-TAVI registry (UMIN000020423), a 1:1 propensity score-matched analysis identified 775 matched pairs. One-year post-TAVI, S3UR showed significantly lower all-cause mortality (10.3% vs. 13.4%, <i>p</i> = 0.026), stroke (0.9% vs. 3.4%, <i>p</i> = 0.001), and heart failure rehospitalization (1.4% vs. 2.7%, <i>p</i> &lt; 0.001) than S3. These differences were pronounced in patients receiving smaller valves (20–23 mm). S3UR demonstrated a larger effective orifice area, lower mean pressure gradient, and lower incidence of paravalvular leakage than S3 at discharge. At 1 year, S3UR showed significantly reduced paravalvular leakage and lower incidences of mean pressure gradient ≥20 mmHg than S3. We concluded that S3UR demonstrated superior hemodynamic performance to S3, exhibiting better prognosis, particularly in patients with smaller valves.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Mechanisms underlying superior outcomes of transcatheter aortic valve implantation with the latest balloon expandable valve

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月2日

查看全文
  • Juri Iwata,
  • Masanori Yamamoto,
  • Ryo Arita,
  • Tomonari Moriizumi,
  • Toshinobu Ryuzaki,
  • Hikaru Tsuruta,
  • Shinichi Shirai,
  • Yusuke Watanabe,
  • Toru Naganuma,
  • Futoshi Yamanaka,
  • Masahiko Noguchi,
  • Hiroshi Ueno,
  • Yohei Ohno,
  • Masaki Izumo,
  • Hidetaka Nishina,
  • Masahiko Asami,
  • Gaku Nakazawa,
  • Fumiaki Yashima,
  • Hirofumi Hioki,
  • Tetsuro Shimura,
  • Kenichi Ishizu,
  • Toshiaki Otsuka,
  • Hideyuki Shimizu,
  • Masaki Ieda,
  • Kentaro Hayashida

摘要

Transcatheter aortic valve implantation (TAVI) using SAPIEN 3 Ultra RESILIA (S3UR) offers improved hemodynamic performance than its former generation, SAPIEN 3 (S3). This study compared 1-year clinical outcomes after TAVI using S3UR and S3. Among 2,369 patients from the OCEAN-TAVI registry (UMIN000020423), a 1:1 propensity score-matched analysis identified 775 matched pairs. One-year post-TAVI, S3UR showed significantly lower all-cause mortality (10.3% vs. 13.4%, p = 0.026), stroke (0.9% vs. 3.4%, p = 0.001), and heart failure rehospitalization (1.4% vs. 2.7%, p < 0.001) than S3. These differences were pronounced in patients receiving smaller valves (20–23 mm). S3UR demonstrated a larger effective orifice area, lower mean pressure gradient, and lower incidence of paravalvular leakage than S3 at discharge. At 1 year, S3UR showed significantly reduced paravalvular leakage and lower incidences of mean pressure gradient ≥20 mmHg than S3. We concluded that S3UR demonstrated superior hemodynamic performance to S3, exhibiting better prognosis, particularly in patients with smaller valves.